BR112022024450A2 - 2-oxo-oxazolidina-5-carboxamidas como inibidores de nav1.8 - Google Patents

2-oxo-oxazolidina-5-carboxamidas como inibidores de nav1.8

Info

Publication number
BR112022024450A2
BR112022024450A2 BR112022024450A BR112022024450A BR112022024450A2 BR 112022024450 A2 BR112022024450 A2 BR 112022024450A2 BR 112022024450 A BR112022024450 A BR 112022024450A BR 112022024450 A BR112022024450 A BR 112022024450A BR 112022024450 A2 BR112022024450 A2 BR 112022024450A2
Authority
BR
Brazil
Prior art keywords
inhibitors
disorders
carboxamides
oxazolidine
oxo
Prior art date
Application number
BR112022024450A
Other languages
English (en)
Inventor
Arasappan Ashok
M Bell Ian
James Bungard Christopher
S Burgey Christopher
M Cox Jason
Guy Guiadeen Deodial
J Kelly Michael Iii
E Layton Mark
Liu Hong
Liu Jian
T Olsen James
J Perkins James
W Schubert Jeffrey
A Shah Akshay
J Stachel Shawn
Wu Zhe
D Vanheyst Michael
Original Assignee
Merck Sharp & Dohme Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme Llc filed Critical Merck Sharp & Dohme Llc
Publication of BR112022024450A2 publication Critical patent/BR112022024450A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C07D263/24—Oxygen atoms attached in position 2 with hydrocarbon radicals, substituted by oxygen atoms, attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

2-OXO-OXAZOLIDINA-5-CARBOXAMIDAS COMO INIBIDORES DE NAV1.8. Novos compostos da fórmula estrutural (I) e os sais dos mesmos farmaceuticamente aceitáveis, são inibidores da atividade do canal Nav1.8 e podem ser úteis no tratamento, prevenção, manuseio, melhora, controle e supressão de doenças mediadas pela atividade do canal Nav1.8. Os compostos da presente invenção podem ser úteis no tratamento, prevenção ou manuseio de distúrbios de dor, distúrbios de tosse, distúrbios de coceira aguda e distúrbios de coceira crônica.
BR112022024450A 2020-06-17 2021-06-14 2-oxo-oxazolidina-5-carboxamidas como inibidores de nav1.8 BR112022024450A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063040463P 2020-06-17 2020-06-17
PCT/US2021/037157 WO2021257418A1 (en) 2020-06-17 2021-06-14 2-oxo-oxazolidine-5-carboxamides as nav1.8 inhibitors

Publications (1)

Publication Number Publication Date
BR112022024450A2 true BR112022024450A2 (pt) 2022-12-27

Family

ID=79268310

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022024450A BR112022024450A2 (pt) 2020-06-17 2021-06-14 2-oxo-oxazolidina-5-carboxamidas como inibidores de nav1.8

Country Status (10)

Country Link
US (1) US20230227441A1 (pt)
EP (1) EP4167994A1 (pt)
JP (1) JP2023530319A (pt)
KR (1) KR20230026404A (pt)
CN (1) CN116056697A (pt)
AU (1) AU2021292061A1 (pt)
BR (1) BR112022024450A2 (pt)
CA (1) CA3182610A1 (pt)
MX (1) MX2022015579A (pt)
WO (1) WO2021257418A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022286511A1 (en) 2021-06-04 2023-11-30 Vertex Pharmaceuticals Incorporated Hydroxy and (halo)alkoxy substituted tetrahydrofurans as modulators of sodium channels
CN117794918A (zh) 2021-06-04 2024-03-29 沃泰克斯药物股份有限公司 经取代的四氢呋喃类似物作为钠通道调节剂
CA3221939A1 (en) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamide analogs as modulators of sodium channels
JP2024520649A (ja) 2021-06-04 2024-05-24 バーテックス ファーマシューティカルズ インコーポレイテッド （２ｒ，３ｓ，４ｓ，５ｒ）－４－［［３－（３，４－ジフルオロ－２－メトキシ－フェニル）－４，５－ジメチル－５－（トリフルオロメチル）テトラヒドロフラン－２－カルボニル］アミノ］ピリジン－２－カルボキサミドを含む固体剤形及び投与レジメン
IL308953A (en) 2021-06-04 2024-01-01 Vertex Pharma N-Hydroalkyl(Hetero)Aryl)Tetrahydrofuran Carboxamides as Natrene Channel Modulators
CA3221788A1 (en) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofuran-2-carboxamides as modulators of sodium channels
TW202408501A (zh) 2022-04-22 2024-03-01 美商維泰克斯製藥公司 用於治療疼痛之雜芳基化合物
WO2023205465A1 (en) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2023205468A1 (en) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2023205463A1 (en) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2023211990A1 (en) 2022-04-25 2023-11-02 Siteone Therapeutics, Inc. Bicyclic heterocyclic amide inhibitors of na v1.8 for the treatment of pain
WO2024123815A1 (en) 2022-12-06 2024-06-13 Vertex Pharmaceuticals Incorporated Process for the synthesis of substituted tetrahydrofuran modulators of sodium channels

Also Published As

Publication number Publication date
CA3182610A1 (en) 2021-12-23
CN116056697A (zh) 2023-05-02
JP2023530319A (ja) 2023-07-14
WO2021257418A1 (en) 2021-12-23
KR20230026404A (ko) 2023-02-24
EP4167994A1 (en) 2023-04-26
AU2021292061A1 (en) 2023-01-19
US20230227441A1 (en) 2023-07-20
MX2022015579A (es) 2023-01-24

Similar Documents

Publication Publication Date Title
BR112022024476A2 (pt) 5-oxopirrolidino-3-carboxamidas como inibidores de nav1.8
BR112022024450A2 (pt) 2-oxo-oxazolidina-5-carboxamidas como inibidores de nav1.8
BR112021008524A8 (pt) 2-amino-n-heteroaril-nicotinamidas como inibidores de nav 1.8
BR112022025805A2 (pt) Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir um distúrbio, condição ou doença
BR112023023186A2 (pt) 3-oxopiperazina carboxamidas de arila e 3-oxopiperazina carboxamidas de heteroarla como inibidores de nav1.8
BR112022026899A2 (pt) Composto representado pela fórmula (i) ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, método de tratamento ou prevenção de uma infecção por vírus, método de inibição da protease 3c viral ou protease 3cl viral em um mamífero e método de tratamento de um distúrbio respiratório
BR112023023239A2 (pt) Carboxamidas de cicloalquil 3-oxopiperazina e carboxamidas de cicloheteroalquil 3-oxopiperazina como inibidores de nav1.8
MY196455A (en) Nitrile-Containing Compounds Useful as Antiviral Agents for The Treatment of a Coronavirus Infection
MX2023007192A (es) Inhibidores de prmt5.
ZA202109010B (en) Compounds and methods for the treatment of covid-19
BR112023002573A2 (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de infecção viral e distúrbio respiratório e método de inibição de protease viral
CL2023001461A1 (es) Inhibidores de prmt5 novedosos
EA202092343A1 (ru) Лечение гнойного гидраденита с использованием ингибиторов jak
MX2023009222A (es) Inhibidores tricíclicos-amido-bicíclicos de prmt5.
BR112022022535A2 (pt) Composto, composição farmacêutica, método de tratamento de câncer, método de inibição seletiva, método de redução de um nível de ros1 ou alk
BR112021020247A2 (pt) Composições e métodos para melhorar a saúde da pele e para o tratamento e prevenção de doenças, distúrbios e afecções associadas a micróbios patogênicos
BR112021025764A2 (pt) Derivado de pirimidina que inibe o crescimento de células cancerígenas e uso medicinal do mesmo
BR112022014861A2 (pt) Métodos de tratamento para deficiência de alfa-1 antittripsina
BR112018076766A2 (pt) derivados de prolinamida alifática
MX2023007150A (es) Compuestos de pirazol que contienen boro, composiciones que los comprenden, métodos y usos de los mismos.
EA202193211A1 (ru) Лечение синуклеопатий
WO2019066548A3 (ko) 심부전의 예방 또는 치료용 약학적 조성물
WO2023230348A3 (en) Dosage regimens for treatment of dengue infection
WO2016178987A3 (en) Preventing or treating viral infection by inhibition of the histone methyltransferase ezh1 or ezh2
WO2019035646A8 (ko) 세포사멸 수용체 저해제를 유효성분으로 포함하는 cx3cl1 케모카인 과발현으로 인한 질환 예방 또는 치료용 조성물